GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Debt-to-Revenue

Affymax, (FRA:A5Y) Debt-to-Revenue : 0.00 (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Affymax, Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Affymax,'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2014 was €0.00 Mil. Affymax,'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2014 was €0.00 Mil. Affymax,'s annualized Revenue for the quarter that ended in Jun. 2014 was €0.12 Mil. Affymax,'s annualized Debt-to-Revenue for the quarter that ended in Jun. 2014 was 0.00.


Affymax, Debt-to-Revenue Historical Data

The historical data trend for Affymax,'s Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, Debt-to-Revenue Chart

Affymax, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 - - 0.09 -

Affymax, Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - N/A N/A N/A -

Competitive Comparison of Affymax,'s Debt-to-Revenue

For the Biotechnology subindustry, Affymax,'s Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymax,'s Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax,'s Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Affymax,'s Debt-to-Revenue falls into.



Affymax, Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Affymax,'s Debt-to-Revenue for the fiscal year that ended in Dec. 2013 is calculated as

Affymax,'s annualized Debt-to-Revenue for the quarter that ended in Jun. 2014 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2014) Revenue data.


Affymax, Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Affymax,'s Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymax, (FRA:A5Y) Business Description

Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines